← feed

Is NCT02823405 results overdue?

Yes — results are overdue. Primary completion was 2018-03-15; the FDAAA-801 reporting deadline (2019-03-15) passed 2701 days ago and no results are posted on ClinicalTrials.gov.

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

NCT IDNCT02823405 ↗
SponsorX4 Pharmaceuticals (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-03-15 (ACTUAL)
Reporting deadline2019-03-15 (completion + 365d)
Days overdue2701
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 b7407309d1d5f84b… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02823405. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →